LRRK2 I1371V Mutation Induces ER Stress, Mitochondrial Dysfunction, and Impaired Mitophagy in Parkinson’s Disease Astrocytes
Objective: This study examines the pathogenic effect of the LRRK2 I1371V mutation on mitochondrial dysfunction, as a result of ER calcium dysregulation, and impaired mitophagy…Evaluation of Perfusion, Iron Deposition, and Neuromelanin MRI Biomarkers Following Mesenchymal Stem Cell Treatment in a Phase 2 Parkinson’s Disease Trial
Objective: Evaluate the effects of allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions on neuroimaging biomarkers in patients with Parkinson’s disease (PD) using different MRI…Bayesian Re-Analysis of Phase I and II Subthalamic Nucleus Perfusion Changes Following Mesenchymal Stem Cell Infusion in Parkinson’s Disease
Objective: To compare subthalamic nucleus (STN) perfusion changes following mesenchymal stem cell (MSC) infusion in Parkinson’s disease (PD) using Bayesian methods in both Phase I…Developing a novel Disease-Specific iPSC Model for Studying MSA Pathogenesis
Objective: This study aims to develop a human iPSC-derived oligodendrocyte (iPSC-OL) model to investigate cell-specific disease mechanisms in MSA. Specifically, we seek to:a)Generate MSA patient-derived…Intrathecal Administration of Human Oral Mucosa Neural Crest Stem Cells in Moderate/Advanced Multiple System Atrophy: Report on Ongoing Phase 1 Study
Objective: This first-in-human study aims to evaluate the safety of hOMNSC300 following intrathecal administration in patients with moderate to advanced MSA. Background: Stem cell therapy…Effect of Allogeneic Bone-Marrow Derived Mesenchymal Stem Cell Therapy on Quality of Life in Patients with Parkinson’s Disease
Objective: To assess the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions on the quality of life (QoL) of patients with…Effects of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy on Motor Complications in Parkinson’s Disease
Objective: To evaluate the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) treatment on motor complications in Parkinson’s disease (PD). Background: Motor…Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson’s Disease: Outcomes Through 3 Years
Objective: To report the safety and clinical outcomes of bemdaneprocel in participants with Parkinson’s disease (PD) through 3 years post transplantation. Background: Bemdaneprocel is an…Impact of Allogeneic Mesenchymal Stem Cells in Motor and Non-Motor Symptoms of Parkinson’s Disease: A Phase 2 Randomized Trial
Objective: To assess the efficacy of repeated intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions in reducing motor and non-motor symptoms in people…Cognitive Improvement in Parkinson’s Disease Patients After Intravenous Mesenchymal Stem Cell Infusion: Results from a Phase 2 Randomized Trial
Objective: Assess the impact of treatment with intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cells (allo-hMSCs) on cognition in patients with mild-moderate Parkinson’s Disease (PD).…
- 1
- 2
- 3
- …
- 6
- Next Page »